A Pharmacogenomic Study of Candesartan in Heart Failure

Phase 4 Completed 300 enrolled Montreal Heart Institute AstraZeneca · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the impact of genetic variations on the response to candesartan in patients with heart failure who are already treated with an ACE inhibitor.

Timeline

Start: 2006-11
Primary completion: 2010-04
Completion: 2010-04

Outcome

Missed primary endpoint

paper Reductions in the primary end points of natriuretic peptides were not significantly associated with AGTR1 A1166C. PMID 29701105 ↗

Publications

de Denus S, Dube MP, Fouodjio R, Huynh T, LeBlanc MH, Lepage S, Sheppard R, Giannetti N, Lavoie J, Mansour A, Provost S, Normand V, Mongrain I, Langlois M, O'Meara E, Ducharme A, Racine N, Guertin MC, Turgeon J, Phillips MS, Rouleau JL, Tardif JC, White M; CANDIID II investigators. A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure. Pharmacogenomics. 2018 May;19(7):599-612. doi: 10.2217/pgs-2018-0004. Epub 2018 Apr 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Candesartan	Unknown	32 mg	—